Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Questions
  10. Schema
  11. Social Networks
  12. External Links
  13. Analytics And Tracking
  14. Libraries
  15. Hosting Providers
  16. CDN Services

We are analyzing https://www.nature.com/articles/srep33897.

Title:
Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation | Scientific Reports
Description:
Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, including the most common mutation, G2019S and is known to play a role in Parkinson’s disease (PD) pathobiology. This has stimulated the development of potent, selective LRRK2 kinase inhibitors as one of the most prevailing disease-modifying therapeutic PD strategies. Although several lines of evidence support beneficial effects of LRRK2 kinase inhibitors, many questions need to be answered before clinical applications can be envisaged. Using six different LRRK2 kinase inhibitors, we show that LRRK2 kinase inhibition induces LRRK2 dephosphorylation and can reduce LRRK2 protein levels of overexpressed wild type and G2019S, but not A2016T or K1906M, LRRK2 as well as endogenous LRRK2 in mouse brain, lung and kidney. The inhibitor-induced reduction in LRRK2 levels could be reversed by proteasomal inhibition, but not by lysosomal inhibition, while mRNA levels remained unaffected. In addition, using LRRK2 S910A and S935A phosphorylation mutants, we show that dephosphorylation of these sites is not required for LRRK2 degradation. Increasing our insight in the molecular and cellular consequences of LRRK2 kinase inhibition will be crucial in the further development of LRRK2-based PD therapies.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

  • Science
  • Education
  • Health & Fitness

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}


Display Ads {🎯}

$63,100 per month
Our calculations suggest that Nature.com earns between $42,042 and $115,616 monthly online from display advertisements.

Keywords {🔍}

lrrk, kinase, pubmed, google, scholar, inhibition, protein, levels, cas, central, inhibitor, parkinsons, dephosphorylation, cells, disease, phosphorylation, destabilization, activity, inhibitors, cell, reduction, treated, nature, article, brain, lung, treatment, analysis, degradation, cellular, mice, leucinerich, repeat, kidney, fig, observed, overexpressing, selective, effects, molecular, czc, ads, pharmacological, proteasomal, mutations, inhibitorinduced, mli, antibody, antilrrk, potent,

Topics {✒️}

nature portfolio mitochondrial dna damage parkinson’s-disease-related mutant alpha-synuclein privacy policy nature alpha-synuclein-mediated dopaminergic neurodegeneration age-dependent bi-phasic alterations author information authors advertising social media comprehensive research synopsis 0/ reprints /english/research/50000715/laboratory italy treated sh-sy5y cells c57bl/6j mice received lrrk2 inhibitor-specific manner enzyme-linked immunosorbent assay full size image mutant lrrk2-induced toxicity11 β-actin mrna levels proteasome-mediated lrrk2 degradation sh-sy5y cells mitochondrial deficits ipsc-derived neural cells lrrk2 pharmacological inhibition mjff-2 anti-lrrk2 antibody lrrk2-based pd therapies molecular neuroscience anti-phospho-lrrk2 antibody pp1-mediated dephosphorylation chloroquine-mediated lysosomal inhibition anti-lrrk2 p-s935 double s910a/s935a mutant lrrk2 primer/probe set lrrk2 kinase inhibitor inhibitor-induced destabilization published reports research protein kinase lrrk2 lrrk2 kinase inhibition full length lrrk2 lrrk2 mrna levels lrrk2 protein destabilization reduced lrrk2 levels personal data lrrk2 exonic variants phosphorylation sites induces lrrk2 protein levels science translational medicine

Questions {❓}

  • LRRK2 kinase Inhibition as a therapeutic strategy for Parkinson’s Disease, where do we stand?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
         description:Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, including the most common mutation, G2019S and is known to play a role in Parkinson’s disease (PD) pathobiology. This has stimulated the development of potent, selective LRRK2 kinase inhibitors as one of the most prevailing disease-modifying therapeutic PD strategies. Although several lines of evidence support beneficial effects of LRRK2 kinase inhibitors, many questions need to be answered before clinical applications can be envisaged. Using six different LRRK2 kinase inhibitors, we show that LRRK2 kinase inhibition induces LRRK2 dephosphorylation and can reduce LRRK2 protein levels of overexpressed wild type and G2019S, but not A2016T or K1906M, LRRK2 as well as endogenous LRRK2 in mouse brain, lung and kidney. The inhibitor-induced reduction in LRRK2 levels could be reversed by proteasomal inhibition, but not by lysosomal inhibition, while mRNA levels remained unaffected. In addition, using LRRK2 S910A and S935A phosphorylation mutants, we show that dephosphorylation of these sites is not required for LRRK2 degradation. Increasing our insight in the molecular and cellular consequences of LRRK2 kinase inhibition will be crucial in the further development of LRRK2-based PD therapies.
         datePublished:2016-09-23T00:00:00Z
         dateModified:2016-09-23T00:00:00Z
         pageStart:1
         pageEnd:9
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1038/srep33897
         keywords:
            Cellular neuroscience
            Kinases
            Molecular medicine
            Molecular neuroscience
            Neurological disorders
            Science
            Humanities and Social Sciences
            multidisciplinary
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep33897/MediaObjects/41598_2016_Article_BFsrep33897_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep33897/MediaObjects/41598_2016_Article_BFsrep33897_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep33897/MediaObjects/41598_2016_Article_BFsrep33897_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep33897/MediaObjects/41598_2016_Article_BFsrep33897_Fig4_HTML.jpg
         isPartOf:
            name:Scientific Reports
            issn:
               2045-2322
            volumeNumber:6
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:E. Lobbestael
               affiliation:
                     name:Laboratory for Neurobiology and Gene Therapy, KU Leuven
                     address:
                        name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:L. Civiero
               affiliation:
                     name:University of Padova
                     address:
                        name:Department of Biology, University of Padova, Padova, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:T. De Wit
               affiliation:
                     name:Laboratory for Neurobiology and Gene Therapy, KU Leuven
                     address:
                        name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J.-M. Taymans
               affiliation:
                     name:UMR-S1172 Jean-Pierre Aubert Research Center – (INSERM - CHRU de Lille - Université de Lille), Early Stages of Parkinson’s Disease Team
                     address:
                        name:UMR-S1172 Jean-Pierre Aubert Research Center – (INSERM - CHRU de Lille - Université de Lille), Early Stages of Parkinson’s Disease Team, Lille, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:E. Greggio
               affiliation:
                     name:University of Padova
                     address:
                        name:Department of Biology, University of Padova, Padova, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:V. Baekelandt
               affiliation:
                     name:Laboratory for Neurobiology and Gene Therapy, KU Leuven
                     address:
                        name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
      description:Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, including the most common mutation, G2019S and is known to play a role in Parkinson’s disease (PD) pathobiology. This has stimulated the development of potent, selective LRRK2 kinase inhibitors as one of the most prevailing disease-modifying therapeutic PD strategies. Although several lines of evidence support beneficial effects of LRRK2 kinase inhibitors, many questions need to be answered before clinical applications can be envisaged. Using six different LRRK2 kinase inhibitors, we show that LRRK2 kinase inhibition induces LRRK2 dephosphorylation and can reduce LRRK2 protein levels of overexpressed wild type and G2019S, but not A2016T or K1906M, LRRK2 as well as endogenous LRRK2 in mouse brain, lung and kidney. The inhibitor-induced reduction in LRRK2 levels could be reversed by proteasomal inhibition, but not by lysosomal inhibition, while mRNA levels remained unaffected. In addition, using LRRK2 S910A and S935A phosphorylation mutants, we show that dephosphorylation of these sites is not required for LRRK2 degradation. Increasing our insight in the molecular and cellular consequences of LRRK2 kinase inhibition will be crucial in the further development of LRRK2-based PD therapies.
      datePublished:2016-09-23T00:00:00Z
      dateModified:2016-09-23T00:00:00Z
      pageStart:1
      pageEnd:9
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1038/srep33897
      keywords:
         Cellular neuroscience
         Kinases
         Molecular medicine
         Molecular neuroscience
         Neurological disorders
         Science
         Humanities and Social Sciences
         multidisciplinary
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep33897/MediaObjects/41598_2016_Article_BFsrep33897_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep33897/MediaObjects/41598_2016_Article_BFsrep33897_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep33897/MediaObjects/41598_2016_Article_BFsrep33897_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsrep33897/MediaObjects/41598_2016_Article_BFsrep33897_Fig4_HTML.jpg
      isPartOf:
         name:Scientific Reports
         issn:
            2045-2322
         volumeNumber:6
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:E. Lobbestael
            affiliation:
                  name:Laboratory for Neurobiology and Gene Therapy, KU Leuven
                  address:
                     name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:L. Civiero
            affiliation:
                  name:University of Padova
                  address:
                     name:Department of Biology, University of Padova, Padova, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:T. De Wit
            affiliation:
                  name:Laboratory for Neurobiology and Gene Therapy, KU Leuven
                  address:
                     name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J.-M. Taymans
            affiliation:
                  name:UMR-S1172 Jean-Pierre Aubert Research Center – (INSERM - CHRU de Lille - Université de Lille), Early Stages of Parkinson’s Disease Team
                  address:
                     name:UMR-S1172 Jean-Pierre Aubert Research Center – (INSERM - CHRU de Lille - Université de Lille), Early Stages of Parkinson’s Disease Team, Lille, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:E. Greggio
            affiliation:
                  name:University of Padova
                  address:
                     name:Department of Biology, University of Padova, Padova, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:V. Baekelandt
            affiliation:
                  name:Laboratory for Neurobiology and Gene Therapy, KU Leuven
                  address:
                     name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Scientific Reports
      issn:
         2045-2322
      volumeNumber:6
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Laboratory for Neurobiology and Gene Therapy, KU Leuven
      address:
         name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium
         type:PostalAddress
      name:University of Padova
      address:
         name:Department of Biology, University of Padova, Padova, Italy
         type:PostalAddress
      name:Laboratory for Neurobiology and Gene Therapy, KU Leuven
      address:
         name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium
         type:PostalAddress
      name:UMR-S1172 Jean-Pierre Aubert Research Center – (INSERM - CHRU de Lille - Université de Lille), Early Stages of Parkinson’s Disease Team
      address:
         name:UMR-S1172 Jean-Pierre Aubert Research Center – (INSERM - CHRU de Lille - Université de Lille), Early Stages of Parkinson’s Disease Team, Lille, France
         type:PostalAddress
      name:University of Padova
      address:
         name:Department of Biology, University of Padova, Padova, Italy
         type:PostalAddress
      name:Laboratory for Neurobiology and Gene Therapy, KU Leuven
      address:
         name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:E. Lobbestael
      affiliation:
            name:Laboratory for Neurobiology and Gene Therapy, KU Leuven
            address:
               name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium
               type:PostalAddress
            type:Organization
      name:L. Civiero
      affiliation:
            name:University of Padova
            address:
               name:Department of Biology, University of Padova, Padova, Italy
               type:PostalAddress
            type:Organization
      name:T. De Wit
      affiliation:
            name:Laboratory for Neurobiology and Gene Therapy, KU Leuven
            address:
               name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium
               type:PostalAddress
            type:Organization
      name:J.-M. Taymans
      affiliation:
            name:UMR-S1172 Jean-Pierre Aubert Research Center – (INSERM - CHRU de Lille - Université de Lille), Early Stages of Parkinson’s Disease Team
            address:
               name:UMR-S1172 Jean-Pierre Aubert Research Center – (INSERM - CHRU de Lille - Université de Lille), Early Stages of Parkinson’s Disease Team, Lille, France
               type:PostalAddress
            type:Organization
      name:E. Greggio
      affiliation:
            name:University of Padova
            address:
               name:Department of Biology, University of Padova, Padova, Italy
               type:PostalAddress
            type:Organization
      name:V. Baekelandt
      affiliation:
            name:Laboratory for Neurobiology and Gene Therapy, KU Leuven
            address:
               name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium
      name:Department of Biology, University of Padova, Padova, Italy
      name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium
      name:UMR-S1172 Jean-Pierre Aubert Research Center – (INSERM - CHRU de Lille - Université de Lille), Early Stages of Parkinson’s Disease Team, Lille, France
      name:Department of Biology, University of Padova, Padova, Italy
      name:Department of Neurosciences, Laboratory for Neurobiology and Gene Therapy, KU Leuven, Leuven, Belgium

External Links {🔗}(168)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk

CDN Services {📦}

  • Crossref

4.83s.